E-Book, Englisch, 538 Seiten, eBook
Reihe: Current Clinical Oncology
ISBN: 978-1-60327-969-7
Verlag: Humana Press
Format: PDF
Kopierschutz: Wasserzeichen (»Systemvoraussetzungen)
Zielgruppe
Research
Autoren/Hrsg.
Weitere Infos & Material
1. Overview.- 2. Introduction to Cancer Surveillance Strategies.- 3. Using Decision Analysis to Model Cancer Surveillance.- 4. Cancer Survivorship: Monitoring the Long-Term and Late Effects of Treatment.- 5. Upper Aerodigestive Tract Carcinoma.- 6. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Europe.- 7. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Japan.- 8. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Canada.- 9. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma.- 10. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma Surveillance Counterpoint: Australia.- 11. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma Surveillance Counterpoint: Japan.- 12. Lung Carcinoma.- 13. Lung Carcinoma Surveillance Counterpoint: Australia.- 14. Lung Carcinoma Surveillance Counterpoint: Japan.- 15. Lung Carcinoma Surveillance Counterpoint: Canada.- 16. Esophagus Carcinoma.- 17. Esophagus Carcinoma Surveillance Counterpoint: Australia.- 18. Esophagus Carcinoma Surveillance Counterpoint: Japan.- 19. Stomach.- 20. Stomach Carcinoma Surveillance Counterpoint: USA.- 21. Stomach Carcinoma Surveillance Counterpoint: Japan.- 22. Pancreatic Adenocarcinoma.- 23. Pancreatic Adenocarcinoma Surveillance Counterpoint: USA.- 24. Pancreatic Adenocarcinoma Surveillance Counterpoint: Europe.- 25. Pancreatic Adenocarcinoma Surveillance Counterpoint: Japan.- 26. Pancreatic Adenocarcinoma Surveillance Counterpoint: Canada.- 27. Liver and Biliary Tract Carcinoma.- 28. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Europe.- 29. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Australia.- 30. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Japan.- 31. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Canada.- 32. Colon and Rectum Carcinoma.- 33. Colon and Rectum Carcinoma Surveillance Counterpoint: USA.- 34. Colon and RectumCarcinoma Surveillance Counterpoint: Australia.- 35. Colon and Rectum Carcinoma Surveillance Counterpoint: Japan.- 36. Colon and Rectum Carcinoma Surveillance Counterpoint: Canada.- 37. Anal Carcinoma.- 38. Anal Carcinoma Surveillance Counterpoint: USA.- 39. Anal Carcinoma Surveillance Counterpoint: Australia.- 40. Anal Carcinoma Surveillance Counterpoint: Japan.- 41. Anal Carcinoma Surveillance Counterpoint: Canada.- 42. Soft Tissue Sarcoma.- 43. Soft Tissue Sarcoma Surveillance Counterpoint: USA.- 44. Soft-Tissue Sarcoma Surveillance Counterpoint: Japan.- 45. Soft Tissue Sarcoma Surveillance Counterpoint: Canada.- 46. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma.- 47. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma Surveillance Counterpoint: Japan.- 48. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma Surveillance Counterpoint: Canada.- 49. Cutaneous Melanoma.- 50. Cutaneous Melanoma Surveillance Counterpoint: USA.- 51. Cutaneous Melanoma Surveillance Counterpoint: Australia.- 52. Cutaneous Melanoma Surveillance Counterpoint: Japan.- 53. Breast Carcinoma.- 54. Breast Carcinoma Surveillance Counterpoint: USA.- 55. Breast Carcinoma Surveillance Counterpoint: Europe.- 56. Breast Carcinoma Surveillance Counterpoint: Australia.- 57. Breast Carcinoma Surveillance Counterpoint: Japan.- 58. Endometrial Carcinoma.- 59. Endometrial Cancer Surveillance Counterpoint: USA.- 60. Endometrial Cancer Surveillance Counterpoint: USA.- 61. Carcinoma of the Endometrium Surveillance Counterpoint: Japan.- 62. Endometrial Carcinoma Surveillance Counterpoint: Canada.- 63. Cervical Carcinoma.- 64. Cervical Carcinoma Surveillance Counterpoint: USA.- 65. Cervical Carcinoma Surveillance Counterpoint: Japan.- 66. Cervical Carcinoma Surveillance Counterpoint: Canada.- 67. Vaginal and Vulvar Carcinoma.- 68. Vaginal and Vulvar Carcinoma Surveillance Counterpoint: Japan.- 69. Ovarian Carcinoma.- 70. Ovarian Carcinoma Surveillance Counterpoint:USA.- 71. Ovarian Cancer Surveillance Counterpoint: Europe.- 72. Ovarian Cancer Surveillance Counterpoint: Japan.- 73. Renal Carcinoma.- 74. Renal Carcinoma Surveillance Counterpoint: Europe.- 75. Renal Carcinoma Surveillance Counterpoint: Japan.- 76. Renal Carcinoma Surveillance Counterpoint: Canada.- 77. Urinary Bladder Carcinoma.- 78. Urinary Bladder Carcinoma Surveillance Counterpoint: Japan.- 79. Urinary Bladder Carcinoma Surveillance Counterpoint: Canada.- 80. Prostate Carcinoma.- 81. Prostate Carcinoma Surveillance Counterpoint: USA.- 82. Prostate Carcinoma Surveillance Counterpoint: USA.- 83. Prostate Carcinoma Surveillance Counterpoint: Europe.- 84. Prostate Carcinoma Surveillance Counterpoint: Japan.- 85. Prostate Carcinoma Surveillance Counterpoint: Canada.- 86. Testicle Carcinoma.- 87. Testicle Carcinoma Surveillance Counterpoint: USA.- 88. Testicle Carcinoma Surveillance Counterpoint: Australia.- 89. Testicle Carcinoma Surveillance Counterpoint: Japan.- 90. Lymphoma.- 91. Lymphoma Surveillance Counterpoint: USA.- 92. Lymphoma Surveillance Counterpoint: Japan.- 93. Lymphoma (Following Autologous Stem Cell Transplant).- 94. Lymphoma (Following Autologous Stem Cell Transplant) Surveillance Counterpoint: Japan.- 95. Leukemia.- 96. Leukemia Surveillance Counterpoint: USA.- 97. Leukemia Surveillance Counterpoint: Japan.- 98. Multiple Myeloma.- 99. Multiple Myeloma Surveillance Counterpoint: USA.- 100. Multiple Myeloma Surveillance Counterpoint: Australia.- 101. Multiple Myeloma Surveillance Counterpoint: Japan.- 102. Multiple Myeloma Surveillance Counterpoint: Canada.- 103. Glioma of the Central Nervous System.- 104. Glioma of the Central Nervous System Surveillance Counterpoint: Europe.- 105. Glioma of the Central Nervous System Surveillance Counterpoint: Australia.- 106. Glioma of the Central Nervous System Surveillance Counterpoint:Japan.